Microbix Biosystems (TSE:MBX) Stock Price Passes Above 50-Day Moving Average – Time to Sell?

Microbix Biosystems Inc. (TSE:MBX) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$0.30 and traded as high as C$0.30. Microbix Biosystems shares last traded at C$0.30, with a volume of 18,000 shares.

Microbix Biosystems Trading Up 4.3%

The company has a market cap of C$41.09 million, a PE ratio of -7.32 and a beta of 0.72. The company has a debt-to-equity ratio of 27.69, a quick ratio of 5.57 and a current ratio of 6.89. The company has a 50 day simple moving average of C$0.30 and a two-hundred day simple moving average of C$0.26.

Microbix Biosystems (TSE:MBX) last posted its quarterly earnings results on Thursday, August 13th. The company reported C($0.01) EPS for the quarter. Microbix Biosystems had a negative return on equity of 18.83% and a negative net margin of 31.72%.The company had revenue of C$4.06 million for the quarter. Sell-side analysts forecast that Microbix Biosystems Inc. will post 0.02 EPS for the current year.

Insider Activity

In related news, Director Martin Marino purchased 115,000 shares of the stock in a transaction dated Thursday, May 28th. The shares were acquired at an average cost of C$0.28 per share, for a total transaction of C$32,200.00. Following the acquisition, the director directly owned 2,000,167 shares in the company, valued at approximately C$560,046.76. The trade was a 6.10% increase in their position. Over the last three months, insiders have acquired 245,500 shares of company stock worth $66,980. Company insiders own 14.00% of the company’s stock.

About Microbix Biosystems

Microbix Biosystems Inc creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs ¿ ) and reference materials (QUANTDx ¿ ) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.